Article info
Editorial commentary
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
- Correspondence to Dr Marcus Koch, Clinical Neurosciences, University of Calgary, Calgary, AB T2N 1N4, Canada; mwkoch{at}ucalgary.ca
Citation
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Publication history
- Received October 26, 2023
- Accepted October 29, 2023
- First published November 14, 2023.
Online issue publication
April 12, 2024
Article Versions
- Previous version (14 November 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.